SPI1 and hepatocellular carcinoma: Unlike conventional immunotherapies that primarily target T cells [77,78], strategies targeting TAM-specific SEs or their upstream regulators, such as SPI1, may offer a novel approach to modulate innate immunity and improve clinical outcomes in HCC patients [79,80].